Healthtech funding in Q4 2022
European Healthtech startup funding raised during Q4 2022.
In Q4 2022, 174 European Healthtech companies closed 182 funding rounds and raised €1.7B in equity funding (excluding debt and grants), down 41.5% versus Q4 2021. Debt rounds added €243M. UK led by capital raised, and EIC Accelerator was the most active investor. Data as of 20 Nov 2026.
Equity funding
€1.7B
-41.5% vs Q4 2021 · excl. debt & grants · +€243M debt
Funding rounds
182
-1.1% vs Q4 2021
Companies
174
Top country
UK
Rank among sectors
#4
9.7% of sector funding
Debt financing
€243M
12.3% of total
Top-10 round share
37.3%
of disclosed capital
Rounds ≥ €100M
3
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q4 2022 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Oct | €726M | 66 |
| Nov | €729M | 62 |
| Dec | €526M | 54 |
Top countries
by € raisedHealthtech — top countries by capital, Q4 2022 — interactive chart.
Data table
| Healthtech — top countries by capital, Q4 2022 | |
|---|---|
| UK | €540M |
| Germany | €346M |
| Switzerland | €305M |
| Denmark | €192M |
| France | €129M |
| Spain | €110M |
| Belgium | €95M |
| Netherlands | €74M |
Stage mix
by € raisedHealthtech — stage mix, Q4 2022 — interactive chart.
Data table
| Healthtech — stage mix, Q4 2022 | |
|---|---|
| Other | €789M |
| Series A | €455M |
| Debt | €243M |
| Series B | €238M |
| Series C | €135M |
| Seed | €58M |
| Grant | €32M |
| Pre-Seed | €14M |
| Series D+ | €13M |
| Crowdfunding | €3.0M |
Exits & M&A
16 Acquisition · 1 IPO17 exits · €2.9B disclosed.
| Immucor | Acquisition | Nov 2022 | €2.0B |
| Neogene Therapeutics | Acquisition | Nov 2022 | €310M |
| Cordis | Acquisition | Oct 2022 | €240M |
| Focus-X Therapeutics | Acquisition | Nov 2022 | €237M |
| Oculis | IPO | Oct 2022 | €82M |
| BModesto | Acquisition | Nov 2022 | €75M |
Top deals
largest disclosed rounds in Q4 2022| Company | Stage | Date | Amount |
|---|---|---|---|
| Vectivbio | Other | Oct 2022 | €127M |
| TauRx Pharmaceuticals | Other | Nov 2022 | €115M |
| Demant AS | Debt | Nov 2022 | €115M |
| Osler Diagnostics | Series C | Nov 2022 | €85M |
| Resolve Biosciences | Series B | Oct 2022 | €72M |
| CatalYm | Series C | Nov 2022 | €50M |
| MinervaX | Debt | Dec 2022 | €50M |
| Univercells | Other | Oct 2022 | €44M |
| Novadip Biosciences | Series B | Nov 2022 | €40M |
| Numares | Other | Dec 2022 | €40M |
| Nucleome Therapeutics | Series A | Oct 2022 | €38M |
| Opna Bio | Series A | Nov 2022 | €37M |
| anokion | Other | Oct 2022 | €36M |
| Mablink Bioscience | Series A | Oct 2022 | €31M |
| Aqemia | Series A | Oct 2022 | €30M |
Top investors
most active in Q4 2022, by deal count- EIC Accelerator6 deals
- Capital Cell4 deals
- European Investment Bank (EIB)4 deals
- APY Ventures3 deals
- Bayern Kapital3 deals
- Bpifrance3 deals
- Calm Storm Ventures3 deals
- Capricorn Partners3 deals
- EIC Fund3 deals
- High-Tech Gründerfonds (HTGF)3 deals